(Total Views: 373)
Posted On: 06/26/2025 2:08:36 PM
Post# of 154563
I don't think we can be sure DSMB will do the right thing.
We saw that in our severe/critical patients trial CD12 ,
they were asked to pay special attention if 2 doses are enough,
And what they said , seeing mortality benefit 82 at 14 days , 50 at 21 days, and 31 at 28 days ??
They said , according to Dr Jay,
Don't change anything , continue what you doing.
And results showing classical picture of undertreated patients..
And we know what happened at the end , 2 doses were not enough and we were not approved ..
We saw that in our severe/critical patients trial CD12 ,
they were asked to pay special attention if 2 doses are enough,
And what they said , seeing mortality benefit 82 at 14 days , 50 at 21 days, and 31 at 28 days ??
They said , according to Dr Jay,
Don't change anything , continue what you doing.
And results showing classical picture of undertreated patients..
And we know what happened at the end , 2 doses were not enough and we were not approved ..
(16)
(0)
